Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Amanda Rodela

Physician Assistant Albuquerque, NM Physician Assistant

NPI 1720744535 CMS profile 11263188

4630 Jefferson Lane Ne, Albuquerque, NM 87109

Open in the dashboard

General payments

$3,960

68 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Rodela of Albuquerque, NM is reported in the CMS Open Payments database as having received $3,960 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $623 20
2024 General $301 10
2023 General $3,036 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Rodela
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amanda Rodela were reported at $623. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amanda Rodela Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $3,036 $167 $52–$557 $160
2024 $301 $178 $55–$600 $164
2025 $623 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Boston Scientific Corporation $1,476 10 payments
  2. Relievant Medsystems, Inc. $1,064 11 payments
  3. Globus Medical, Inc. $457 12 payments
  4. Medtronic, Inc. $455 10 payments
  5. Nalu Medical, Inc. $187 9 payments
  6. Nevro Corp. $153 7 payments
  7. AbbVie, Inc. $73 4 payments
  8. Vertex Pharmaceuticals Incorporated $60 3 payments
  9. Averitas Pharma Inc. $19 1 payment
  10. Hollister Incorporated $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $2,138 59 payments
  2. Travel and Lodging $1,822 9 payments
Products named General payments · program years 2023–2025
  1. Intracept Pain $1,085 12 payments
  2. Intracept Pain $1,064 11 payments
  3. Intracept Pain $1,064 11 payments
  4. Intracept Pain $1,064 11 payments
  5. Senza Spinal Cord Stimulator $457 12 payments
  6. Nalu Neurostimulation System $187 9 payments
  7. INTELLIS ADAPTIVESTIM $171 6 payments
  8. Senza Spinal Cord Stimulator $153 7 payments
  9. OSTEOCOOL RF ABLATION SYSTEM $144 1 payment
  10. SYNCHROMEDII $95 1 payment
  11. Other $299 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

629

Median for Physician Assistant: 241

Drug cost

$17,397

Median for Physician Assistant: $4,110

Branded share of claims

32.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naloxone Hcl Generic 51 $3,529
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 145 $2,837
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 13 $2,585
Oxycodone Hcl Generic 93 $2,244
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 28 $1,321
Buprenorphine Hcl Generic 18 $1,037
Gabapentin Generic 75 $966
Tramadol Hcl Generic 80 $792
Hydromorphone Hcl Generic 16 $705
Pregabalin Generic 41 $481

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$69,988

Medicare's payments for the services billed

Medicare patients

247

Average age 73

Services billed

904

158 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Chronic kidney disease 29%
Depression 28%
Ischemic heart disease 26%
Osteoporosis 20%
Heart failure 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in New Mexico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record